Investing.com -- The U.S. Centers for Medicare & Medicaid Services (CMS) on Tuesday announced a new list of branded medications for the third round of the Medicare Drug Price Negotiation Program. The ...

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

My top 10 things to watch Tuesday, Jan. 27 1. The S & P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings tomorrow evening (Meta Platforms and Microsoft ) and Thursday ...

The S&P 500 rose as traders braced for a big week, with key earnings reports and a U.S. monetary policy meeting.

Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable ...

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a ...

It feels like a great rotation out of the Magnificent Seven has already kicked off just over a quarter ago. Undoubtedly, the ...

One exchange-traded fund (ETF) that tracks the Large Cap Growth Index is the Vanguard Growth ETF ( VUG +0.68%). It has ...

Eaton Vance Enhanced Equity Income Fund is a Strong Buy for superior balance of yield & total return in covered call space.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit ...